Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study

Int J Rheum Dis. 2024 Mar;27(3):e15091. doi: 10.1111/1756-185X.15091.
No abstract available

Publication types

  • Observational Study
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Arthritis, Psoriatic* / diagnosis
  • Arthritis, Psoriatic* / drug therapy
  • Arthritis, Rheumatoid* / diagnosis
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / epidemiology
  • Humans
  • Italy

Substances

  • golimumab
  • Antibodies, Monoclonal